PTC Therapeutics Provides a Corporate Update and Reports First Quarter Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
PTC Therapeutics (PTCT) Misses Q1 EPS by 24c
May 3, 2022 4:51 PM EDTPTC Therapeutics (NASDAQ: PTCT) reported Q1 EPS of ($1.78), $0.24 worse than the analyst estimate of ($1.54). Revenue for the quarter came in at $148.73 million versus the consensus estimate of $146.9 million.
For earnings history and earnings-related data on PTC Therapeutics (PTCT) click here.
... More